This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Genome Technology Center | |
|---|---|
| Name | Genome Technology Center |
| Established | 2000 |
| Type | Research facility |
| Director | Dr. Jane Doe |
| Location | New Haven, Connecticut |
| Affiliation | Yale University |
Genome Technology Center
The Genome Technology Center is a multidisciplinary research facility focused on high-throughput sequencing, genomic analysis, and translational genomics. It supports investigators from academic institutions, biotechnology companies, and clinical centers by providing access to next-generation sequencing, single-cell genomics, and bioinformatics infrastructure. The Center functions as a hub for collaboration among laboratories, core facilities, and consortia to advance projects in cancer genomics, infectious disease, and population genetics.
The Center houses platforms for whole-genome sequencing, exome sequencing, RNA sequencing, and epigenomics to serve researchers from Yale University, Columbia University, Harvard University, Stanford University, Broad Institute, and industry partners such as Illumina, Thermo Fisher Scientific, PacBio, and Oxford Nanopore Technologies. Staff includes faculty-affiliated investigators from Department of Genetics (Yale), computational scientists with ties to Cold Spring Harbor Laboratory, and clinical genomics teams connected to Yale New Haven Hospital and Mayo Clinic. The facility integrates resources from consortia such as the Human Genome Project, the 1000 Genomes Project, the ENCODE Project and clinical initiatives like the All of Us Research Program to provide scalable services. Training programs link with graduate programs at Yale School of Medicine, postdoctoral programs at NIH, and workshops sponsored by Broad Institute.
The Center was founded in response to the needs that emerged after the completion of the Human Genome Project and the proliferation of next-generation sequencing technologies at institutions including the Broad Institute and Wellcome Sanger Institute. Early leadership included collaborations with investigators from Cold Spring Harbor Laboratory, Howard Hughes Medical Institute, and computational groups from MIT. Expansion phases paralleled milestones at technology companies such as Illumina and the commercialization of platforms by PacBio and Oxford Nanopore Technologies. The Center participated in large-scale consortia like the 1000 Genomes Project and undertook infrastructure upgrades following initiatives by National Institutes of Health and the National Human Genome Research Institute. Over time it broadened service offerings to include single-cell genomics influenced by advances at Broad Institute and spatial transcriptomics developed in collaborative projects with Stanford University and Harvard Medical School.
Core technologies include high-throughput short-read platforms from Illumina, long-read sequencers from PacBio and Oxford Nanopore Technologies, single-cell platforms from 10x Genomics, and spatial profiling systems influenced by tools from NanoString Technologies. The bioinformatics core maintains compute clusters interoperable with Amazon Web Services, Google Cloud Platform, and NIH STRIDES initiatives, and uses pipelines from projects such as GATK and tools developed at Broad Institute. Laboratory infrastructure complies with standards from Clinical Laboratory Improvement Amendments and partners with clinical laboratories at Yale New Haven Hospital and diagnostic units used by Mayo Clinic. Quality-control workflows reference datasets from 1000 Genomes Project and Genome in a Bottle to benchmark performance.
Research programs span cancer genomics in collaboration with Memorial Sloan Kettering Cancer Center and Dana-Farber Cancer Institute, infectious disease genomics tied to projects with Centers for Disease Control and Prevention, and population genetics studies linked to All of Us Research Program and cohorts like Framingham Heart Study. Projects include tumor-normal sequencing consortia with The Cancer Genome Atlas investigators, antimicrobial resistance surveillance studies partnering with World Health Organization, and rare disease diagnostics collaborating with Undiagnosed Diseases Network. Translational efforts tie into precision oncology trials at Dana-Farber Cancer Institute and clinical sequencing protocols at Yale New Haven Hospital.
The Center offers services including library preparation, sequencing, data analysis, variant interpretation, and clinical reporting for partners such as Yale School of Medicine, biotechnology firms, and nonprofit consortia. It collaborates with technology vendors like Illumina and 10x Genomics for pilot evaluations, and academic partners including Columbia University and Harvard Medical School for method development. Training and outreach programs have been coordinated with Cold Spring Harbor Laboratory courses, workshops at Broad Institute, and seminars sponsored by National Institutes of Health. Data-sharing agreements align with standards from Global Alliance for Genomics and Health and regulatory frameworks informed by Food and Drug Administration guidance.
Governance is overseen by a scientific advisory board composed of faculty from Yale School of Medicine, representatives from partner institutions such as Harvard Medical School and Columbia University, and liaisons from funding bodies including National Institutes of Health and National Science Foundation. Funding sources include institutional support from Yale University, grants from NIH, philanthropic gifts from foundations like Gordon and Betty Moore Foundation and Bill & Melinda Gates Foundation, and fee-for-service revenue from industry collaborations with companies like Illumina and Thermo Fisher Scientific.
The Center contributed data and analytical pipelines to international efforts including the 1000 Genomes Project, the ENCODE Project, and collaborative publications with investigators from Broad Institute, Cold Spring Harbor Laboratory, and Dana-Farber Cancer Institute. It supported clinical diagnoses in rare disease cases submitted to the Undiagnosed Diseases Network and aided outbreak sequencing during public health responses coordinated with Centers for Disease Control and Prevention and World Health Organization. Technological evaluations conducted in partnership with Illumina, PacBio, and Oxford Nanopore Technologies informed adoption of long-read sequencing in clinical research. The facility’s trainees have taken positions at institutions such as Broad Institute, Stanford University, and National Institutes of Health.
Category:Genomics centers